Through collaboration with the HRI’s Vascular Complications Group, we continue to study potential therapies to boost TRAIL, a novel mediator with marked anti-inflammatory and anti-atherosclerotic properties, in patients with coronary disease.
This work has resulted in several presentations at international cardiovascular meetings, and two publications.